

## Special Issue

# Recent Advances in Arthritis and Tendinopathy

### Message from the Guest Editors

Arthritis and tendinopathy are two of the most common musculoskeletal disorders. However, current clinical treatment strategies cannot yield satisfactory results. Recently, an increasing number of biomarkers, microRNAs, lncRNAs, and cellular responses have been proposed to be involved in pathogenesis and would be therapeutic candidates in addition to stem cells, exosomes, biomaterials, and nanomaterials. Reducing inflammation, apoptosis, or senescence, enhancing M2 macrophage polarization, and maintaining extracellular matrix homeostasis in cartilage or tendons are common therapeutic approaches. Therefore, the Special Issue aims to highlight “diagnosis” and “treatment” of arthritis and tendinopathy. Articles presenting new strategies supported by experimental or clinical results and comprehensive evidence-based reviews are welcome. This issue will provide new insight into pathogenesis and treatment of arthritis and tendinopathy.

### Guest Editors

Dr. Po-Ting Wu  
Dr. Chung-Hwan Chen  
Dr. Tulyaprupek Tawonsawatruk

### Deadline for manuscript submissions

closed (31 May 2024)



## Biomedicines

an Open Access Journal  
by MDPI

Impact Factor 3.9  
CiteScore 6.8  
Indexed in PubMed



[mdpi.com/si/155865](https://mdpi.com/si/155865)

*Biomedicines*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[biomedicines@mdpi.com](mailto:biomedicines@mdpi.com)

[mdpi.com/journal/  
biomedicines](https://mdpi.com/journal/biomedicines)





# Biomedicines

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.9  
CiteScore 6.8  
Indexed in PubMed



[mdpi.com/journal/  
biomedicines](https://mdpi.com/journal/biomedicines)



## About the Journal

### Message from the Editor-in-Chief

*Biomedicines* (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

---

### Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

---

### Author Benefits

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPLus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

#### Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).